Role of PARP Inhibitors in BRCA-Related Malignancies

Sana Iqbal, PharmD; Mohammad A. Rattu, PharmD, BCOP, BCPS, BCGP; Neal Shah, PharmD

Disclosures

US Pharmacist. 2018;43(9):HS10-HS17. 

In This Article

Conclusion

PARP enzyme inhibition is a rational, specific approach in the ever-growing field of oncology. There are ongoing studies with drug combinations as well as investigations of potential utility in other malignancies. Current data support the use of PARP inhibitors to prolong PFS, but the drug class has yet to demonstrate statistically significant improvements in OS. Pharmacists should remain involved with other members of the healthcare team, in order to educate patients regarding PARP inhibitors' adverse effects and their management.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....